Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | HTR5A | P47898 | 2/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3045182 | 0.90 | HDAC1 (0.43) | HDAC1HTTSLC2A1POLB | |
| Trifluoroacetic Acid SCHEMBL1875536 | 0.87 | HTT (0.41) | HTTNAMPT | |
| Trifluoroacetic Acid SCHEMBL3037461 | 0.87 | S1PR2 (0.38) | HTR5ASLC2A1 | |
| Trifluoroacetic Acid SCHEMBL3051512 | 0.87 | HTT (0.43) | HDAC1HTTNAMPTHTR5ASLC2A1 | |
| Trifluoroacetic Acid SCHEMBL3051658 | 0.86 | HTT (0.42) | HDAC1HTTNAMPTHDAC3HDAC2 | |
| Trifluoroacetic Acid SCHEMBL3051308 | 0.85 | HTR5A (0.44) | HDAC1HTR5AHDAC3HDAC2NCOR2 | |
| Trifluoroacetic Acid SCHEMBL3051554 | 0.84 | KDM4E (0.47) | HDAC1NAMPTHTR5ASLC2A1 | |
| Trifluoroacetic Acid SCHEMBL3041965 | 0.83 | HDAC1 (0.47) | HDAC1HTR5AHDAC3HDAC2 | |
| Trifluoroacetic Acid SCHEMBL3047546 | 0.82 | HTT (0.40) | HDAC1HTTNAMPTHDAC2 | |
| Trifluoroacetic Acid SCHEMBL3046203 | 0.82 | HTR5A (0.46) | HTR5ASLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | HDAC1 2221/4885HTT 1472/4885NAMPT 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.